Seniors vaccine safety surveillance Zoster (Shingles) vaccine safey surveillance data In the context of no safety signals identified during two years of surveillance in over 18,000 participants, AusVaxSafety concluded active surveillance of zoster vaccine safety in November 2018. It is important to re-emphasise that zoster vaccine should not be given to immunocompromised individuals. For more information please refer to the Therapeutic Goods Administration (TGA) website. Last updated 13/12/2019 18,655 Seniors responded to an SMS about their health a few days after their Zoster vaccinations. 91.7% reported no adverse events 91.7% reported no adverse events 8.3% reported any adverse event, including... 0.3% who reported going to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 1,557 Seniors reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived. Influenza vaccine safety surveillance data Surveillance of 2020 influenza vaccine safety commenced from 9 April 2020. The current reported event rates are consistent with what are expected according to the existing data. For more information on how AusVaxSafety conducts active vaccine safety surveillance click here. Last updated 04/09/2020 81,786 Seniors responded to an SMS about their health a few days after their influenza vaccinations. 94.3% reported no adverse events 94.3% reported no adverse events 5.7% reported any adverse event, including... 0.2% who reported going to a doctor or emergency department in the days after vaccination.The adverse events they reported were similar to the types of adverse events reported overall 4,690 Seniors reported one or more adverse events. The most commonly reported were: These symptoms are known to occur after vaccination. They are generally mild and short-lived.
